DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the STRIDES PHARMA SCI LTD (STAR) share price today?

STRIDES PHARMA SCI LTD (STAR) is trading at ₹1,074.9 on the NSE, up 2.45% on the day. Source: DocStoX.

What is the PE ratio of STRIDES PHARMA SCI LTD?

STRIDES PHARMA SCI LTD has a price-to-earnings (PE) ratio of 17.8 in the Healthcare sector.

What is the market capitalisation of STRIDES PHARMA SCI LTD?

STRIDES PHARMA SCI LTD has a market capitalisation of approximately ₹9,929 crore.

STRIDES PHARMA SCI LTD

STAR·NSE·Healthcare

₹1,074.90▲ +25.70 (+2.45%)

Healthcare · Pharmaceuticals

High-quality returns — 20% on equity

Day₹1007.50

₹1100.00

52W₹769

₹123166%

Open

₹1050.00

High

₹1100.00

Low

₹1007.50

Prev Close

₹1049.20

Volume

4.27L

VWAP

₹1039.16

Snapshot

Key fundamentals

Market Cap

₹9,929 Cr

P/E Ratio

17.81Fair

P/B Ratio

3.34

EPS

₹60.34

Book Value

₹337.00

ROE

20.40%Strong

ROCE

19.00%Efficient

Dividend Yield

0.37%

Debt / Equity

0.57Moderate

Face Value

₹10.00

52W High

₹1231.00

52W Low

₹768.65

Sector

Healthcare

Industry

Pharmaceuticals

Avoid

Narrow moatMedium uncertainty

Fair value estimate

₹516

▼ 52.0%downside

Trading at ₹1,075 — 52% above our estimate

BearFair valueBull

₹438₹516₹676

/100

Business quality — Solid

Growth 39Profitability 66Efficiency 28Valuation 76

Plain English

Our view

High-quality returns — 20% on equity
Strong returns on equity (20%)
Fundamental red flags (Piotroski 1/9)

How we got there

Fair value methods

Residual income

20% ROE fading to 13% over ~10 yrs, on ₹337 book

₹471

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹676

Analyst target

No analyst coverage

—

Blended fair value₹516

What the numbers say

Investment thesis

Bull case

Strong returns on equity (20%)

Bear case

Fundamental red flags (Piotroski 1/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

17.8Fair

Below 15× is value territory; above 35× prices in strong growth

ROE

20.4%Strong

Above 15% is considered healthy for Indian equities

ROCE

19.0%Efficient

Above 18% means capital is working hard

Debt/Eq

0.57Moderate

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹9,929 Cr

P/B

3.34

EPS

₹60.34

Div Yield

0.37%

What changed

Recent changes

Foreign investors-0.8% stake last quarter
Domestic institutions+1.4% stake last quarter
Promoters+0.05% stake last quarter

What matters

News impact

Overview

Valuation

Attractive

P/E 17.8×

Growth

Steady

+10% rev CAGR

Profitability

Excellent

20.4% ROE

Financial health

Comfortable

D/E 0.57

Momentum

N/A

No technicals

Today

Trading activity

Delivery %49.4%

Turnover₹4438.47L Cr

Trades30,934

VWAP₹1039.16

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+9.6%

+7.9%

10Y

+5.4%

Profit

—

+17.4%

10Y

+19.7%

EPS

—

+15.1%

10Y

+17.4%

Profile

Pros

Company has delivered good profit growth of 20.6% CAGR over last 5 years
Company has a good return on equity (ROE) track record: 3 Years ROE 57.2%

Watch-outs

Cons

Stock is trading at 3.21 times its book value
The company has delivered a poor sales growth of 7.94% over past five years.
Promoter holding is low: 27.9%
Tax rate seems low
Promoters have pledged 27.3% of their holding.

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Promoters raised their stake by 0.05 pts; foreign investors sold 0.84 pts; domestic institutions added 1.43 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

28%

Promoter

Promoters

27.9%+0.05

Public

20.8%-0.64

FII / FPI

28.7%-0.84

DII

14.4%+1.43

Others

8.2%

Total shareholders

86,616+1,027 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter27.91%

FII28.68%

DII14.45%

Government0.01%

Public20.78%

Others8.17%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions